Publication | Open Access

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

UrologyGenitourinary CancerMedicinePharmacologyPharmacotherapyProstatic DiseaseOncologyPhase 1Endocrine-related CancerJapanese Patients